[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SMT201600156B - Trattamento dell’osteoartrite - Google Patents

Trattamento dell’osteoartrite

Info

Publication number
SMT201600156B
SMT201600156B SM201600156T SM201600156T SMT201600156B SM T201600156 B SMT201600156 B SM T201600156B SM 201600156 T SM201600156 T SM 201600156T SM 201600156 T SM201600156 T SM 201600156T SM T201600156 B SMT201600156 B SM T201600156B
Authority
SM
San Marino
Prior art keywords
osteoartritis
treatment
Prior art date
Application number
SM201600156T
Other languages
English (en)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of SMT201600156B publication Critical patent/SMT201600156B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM201600156T 2008-12-22 2016-06-01 Trattamento dell’osteoartrite SMT201600156B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
SMT201600156B true SMT201600156B (it) 2016-08-31

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600156T SMT201600156B (it) 2008-12-22 2016-06-01 Trattamento dell’osteoartrite

Country Status (19)

Country Link
US (4) US9243061B2 (it)
EP (2) EP3056217B1 (it)
JP (3) JP5727379B2 (it)
KR (2) KR101898982B1 (it)
CN (2) CN102271705A (it)
AU (1) AU2009329814B2 (it)
BR (1) BRPI0918356B1 (it)
CA (1) CA2746827C (it)
CY (1) CY1117698T1 (it)
DK (1) DK2376121T4 (it)
ES (2) ES2572368T5 (it)
HK (1) HK1226938A1 (it)
HR (1) HRP20160577T4 (it)
HU (1) HUE028615T2 (it)
PL (1) PL2376121T5 (it)
RU (2) RU2712273C2 (it)
SI (2) SI2376121T1 (it)
SM (1) SMT201600156B (it)
WO (1) WO2010071924A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572368T5 (es) 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
PE20151079A1 (es) 2012-09-20 2015-08-07 Morphosys Ag Tratamiento para artritis reumatoide
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0482086A1 (en) 1989-07-14 1992-04-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
AU637133B2 (en) 1989-08-11 1993-05-20 Amrad Operations Pty. Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
WO1994011404A1 (en) 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
EP1442132A2 (en) * 2001-10-26 2004-08-04 Novartis AG Methods for the treatment of osteoarthritis and compositions thereof
ATE509032T1 (de) 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
CA2555688C (en) † 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2005094889A1 (ja) * 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
CA2575439A1 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
PT3620171T (pt) * 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
BRPI0619224A2 (pt) * 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
HUE032584T2 (en) * 2006-02-08 2017-09-28 Morphotek Inc Antigen GM-CSF peptides and GM-CSF antibodies
SI2423230T1 (sl) * 2006-03-27 2013-09-30 Medimmune Limited Vezni ÄŤlen za receptor GM-CSF
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
MX2009005398A (es) * 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
US7879856B2 (en) * 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
DK2215119T3 (da) 2007-11-13 2013-02-04 Evec Inc Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
MX2010010503A (es) † 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
MX2010011761A (es) 2008-04-28 2010-11-30 Kalobios Pharmaceuticals Inc Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
ES2572368T5 (es) 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
RU2630969C2 (ru) † 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies

Also Published As

Publication number Publication date
US20180066062A1 (en) 2018-03-08
KR101898982B1 (ko) 2018-09-14
EP3056217B1 (en) 2021-06-30
RU2016102339A3 (it) 2019-07-29
HRP20160577T1 (hr) 2016-07-29
RU2712273C2 (ru) 2020-01-28
KR101799264B1 (ko) 2017-11-20
JP2017200933A (ja) 2017-11-09
BRPI0918356B1 (pt) 2022-03-08
BRPI0918356A2 (pt) 2020-10-06
ES2886063T3 (es) 2021-12-16
PL2376121T5 (pl) 2021-09-27
CY1117698T1 (el) 2017-05-17
ES2572368T5 (es) 2021-12-16
CA2746827A1 (en) 2010-07-01
RU2016102339A (ru) 2018-11-21
SI2376121T1 (sl) 2016-07-29
AU2009329814B2 (en) 2015-06-18
ES2572368T3 (es) 2016-05-31
WO2010071924A1 (en) 2010-07-01
SI2376121T2 (sl) 2021-11-30
EP2376121A4 (en) 2013-04-03
US20200247895A1 (en) 2020-08-06
JP2012512815A (ja) 2012-06-07
KR20110128273A (ko) 2011-11-29
HUE028615T2 (en) 2016-12-28
US20160185868A1 (en) 2016-06-30
EP2376121B1 (en) 2016-03-09
US20120003234A1 (en) 2012-01-05
CN102271705A (zh) 2011-12-07
CA2746827C (en) 2018-01-23
EP2376121B2 (en) 2021-06-09
DK2376121T3 (en) 2016-05-30
CN106397591A (zh) 2017-02-15
US9243061B2 (en) 2016-01-26
DK2376121T4 (da) 2021-08-16
HRP20160577T4 (hr) 2021-08-20
KR20170128630A (ko) 2017-11-22
JP2015143233A (ja) 2015-08-06
EP2376121A1 (en) 2011-10-19
JP5727379B2 (ja) 2015-06-03
AU2009329814A1 (en) 2010-07-01
PL2376121T3 (pl) 2016-12-30
HK1226938A1 (zh) 2017-10-13
RU2011127334A (ru) 2013-01-27
EP3056217A1 (en) 2016-08-17
JP6458086B2 (ja) 2019-01-23

Similar Documents

Publication Publication Date Title
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
BRPI0916931A2 (pt) agentes terapêuticos
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI0910854A2 (pt) métodos de tratamento
DK2222272T3 (da) Behandling af luftvejssygdom
SMT201600156B (it) Trattamento dell’osteoartrite
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
GB0818074D0 (en) Treatment of biofilms
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
DK2330887T3 (da) Behandlingsindretning
DK2252317T3 (da) Behandling af makuladegeneration
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
FI20085693A0 (fi) Biosignaalin prosessointi
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
DK2501381T3 (da) Behandling af atrieflimmer
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
DK2173197T3 (da) Fremgangsmåde
FR2930723B1 (fr) Orthese de cheville
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0909764A2 (pt) compostos terapêuticos
SMT201600224B (it) Trattamento dell'osteoporosi
BRPI0906879A2 (pt) Compostos terapêuticos